Physician profile
Doris Day
NPI 1851384028
$309,824.28
in general payments reported to CMS, 2019-2025
30 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $58K · 2021: $17K · 2022: $65K · 2023: $16K · 2024: $1,695 · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $16K · Food and Beverage: $11K · Travel and Lodging: $294 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,950.00 |
| Consulting Fee | $15,503.33 |
| Food and Beverage | $10,528.99 |
| Travel and Lodging | $293.86 |
| Education | $279.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $111,486.87 | 2019-2023 | Xeomin |
| Allergan, INC. | $53,407.64 | 2019-2022 | |
| Revance Therapeutics, INC. | $51,805.91 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $33,421.55 | 2019-2025 | Dysport, Aklief |
| Solta Medical, A Division of Bausch Health US, LLC | $23,809.04 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $9,657.44 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $9,465.97 | 2019-2025 | Cabtreo, Jublia |
| Dermira, INC. | $4,426.34 | 2019-2021 | |
| Abbvie INC. | $3,301.66 | 2020-2025 | Botox |
| Botanix Sb INC | $2,273.58 | 2025 | Sofdra |
| Epi Health, LLC | $1,704.97 | 2020-2022 | |
| Almirall LLC | $972.61 | 2024-2025 | Klisyri |
| Incyte Corporation | $901.28 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $474.13 | 2021-2025 | Tremfya |
| Ucb, INC. | $464.55 | 2022-2025 | Bimzelx, Cimzia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $415.60 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $396.38 | 2022-2025 | Otezla, Otezla |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2023 | Sumadan Wash |
| Sun Pharmaceutical Industries INC. | $200.34 | 2021-2022 | |
| Pfizer INC. | $175.70 | 2022-2025 | |
| Journey Medical Corporation | $163.95 | 2020-2025 | |
| Leo Pharma INC. | $105.55 | 2021-2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $94.92 | 2025 | |
| Genzyme Corporation | $92.42 | 2023-2025 | |
| Dermavant Sciences, INC. | $78.36 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $69.45 | 2021 | |
| Organon LLC | $48.04 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.58 | 2020 | |
| Fidia Pharma USA INC. | $18.07 | 2024 | |
| Sebela Pharmaceuticals INC. | $17.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.